Nasdaq · Healthcare
LivaNova PLC (LIVN)
As-reported financials and recent SEC filings for LivaNova PLC, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$1.39B
Net income
$-242.5M
Net margin
-17.5%
Diluted EPS
$-4.45
ROE
-20.2%
P/E (TTM)
42.6×
Market cap
$4.58B
Debt / equity
0.3×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $1.39B | $1.25B | $1.15B | $1.02B | $1.04B |
| Gross profit | $939.9M | $853.5M | $755.8M | $707.2M | $706.0M |
| Operating income | $199.4M | $129.1M | $-68.5M | $-76.8M | $-784,000 |
| Net income | $-242.5M | $63.2M | $17.5M | $-86.2M | $-135.8M |
| Diluted EPS | $-4.45 | $1.16 | $0.32 | $-1.61 | $-2.68 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-06-17
View on EDGAR →42026-06-17
View on EDGAR →42026-06-17
View on EDGAR →42026-06-17
View on EDGAR →42026-06-17
View on EDGAR →42026-06-17
View on EDGAR →42026-06-17
View on EDGAR →42026-06-17
View on EDGAR →Go deeper on LIVN
Search LivaNova PLC’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.